All Life Sciences & Technology News
Top stories summarized by our editors
3/29/2017

Roche Holding's injectable Ocrevus, or ocrelizumab, has been approved by the FDA as a treatment for the primary progressive form of multiple sclerosis. The approval was based on a clinical study that showed patients being treated with Ocrevus were 47% more likely to have no disease progression than patients taking a placebo.

Full Story:
Reuters
More Summaries:
FDA, Roche, Ocrevus, ocrelizumab
3/29/2017

Researchers reported in Nature Communications that they identified and quantified 10,000 proteins in each of 24 patient-derived xenografts of breast tumors of different subtypes, and a "substantial" number are potentially treatment targets. Growing human tumors in laboratory mice mimics the tumors' natural environment and "offers a closer representation of the tumor's growth environment to study cancer drugs than cells growing on a laboratory plastic dish," researcher Matthew Ellis said.

More Summaries:
Nature Communications
3/29/2017

Bristol-Myers Squibb has entered into a collaboration with the Cancer Research Institute and the Parker Institute for Cancer Immunotherapy with the goal of accelerating the identification and development of cancer immunotherapies. Under the agreement, BMS will use its bioanalytical expertise, advanced translational tools and precision immunotherapy, while the institutes will offer clinical proposals and study support.

3/29/2017

Uncertain support from congressional Republicans, as well as a time crunch to respond to the expiration of a continuing budget resolution, mean the Trump administration's proposal to cut this year's budget for public health agencies will likely not pass without major modifications, said Steven Grossman, executive director of the Alliance for a Stronger FDA. The proposed budget for the rest of fiscal 2017 would slash $1.23 billion from the NIH's budget, trim $40 million from the FDA's budget and cut $50 million from the CMS and $314 million from the CDC.

Full Story:
BioCentury
3/29/2017

Ono Pharmaceutical has been granted exclusive development and commercialization rights to a multispecific immuno-oncology antibody drug developed through Numab Therapeutics' discovery platform. In exchange, Numab is entitled to an upfront payment of $261.9 million, milestone fees, tiered royalties and research funding.

Full Story:
BioCentury
3/29/2017

A round of Series C financing has pulled in $22 million for Antiva Biosciences. The company's lead candidate, ABI-1968, is in early-stage studies as a topical treatment for high-grade cervical intraepithelial neoplasia and anal intraepithelial neoplasia.

Full Story:
BioCentury
More Summaries:
neoplasia, Antiva Biosciences
3/29/2017

President Donald Trump's proposed budget for the USDA in fiscal 2018 is $17.9 billion, a $4.7 billion reduction from this year's $22.6 billion in funding. The budget calls for the Agricultural Research Service's research funding to prioritize food safety and nutrition issues, boosting farming productivity and sustaining natural resources.

3/29/2017

Green chemistry is working to reduce the chemical industry's environmental impact by shifting from oil to renewable sources, and it also focuses on improving energy efficiency and reducing toxic waste, writes Alex Bissember, a senior lecturer at the University of Tasmania. Although green chemistry has seen technological advancements in the 20 years since its establishment, the industry still faces challenges, including the development of more biodegradable plastics and capturing and fixing greenhouse gases, Bissember writes.

3/29/2017

Cara Therapeutics' lead candidate, I.V. CR845, has met the primary endpoint of a Phase II/III study in which the drug showed a higher percentage of reduction in mean worst itching score than a placebo in patients with uremic pruritus. The drug also met the secondary endpoint, in which patients experienced 100% greater reduction from baseline in their Skindex-10 score using I.V. CR845 compared with those using the placebo treatment.

3/29/2017

Regeneron Pharmaceuticals has received approval from the FDA for its injectable Dupixent, or dupilumab, which is indicated as a treatment for adult patients with moderate to severe atopic dermatitis or eczema that is not controlled adequately by topical therapies. Regeneron said Dupixent will be launched with an annual wholesale cost of $37,000 before patient assistance programs, discounts and rebates.